Australia - inglese - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: hyprolose; sodium lauryl sulfate; lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - tadacip is indicated for the treatment of: ? erectile dysfunction (ed) in adult males ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; sodium lauryl sulfate; purified talc; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; triacetin; iron oxide yellow - cialis is indicated for the treatment of: erectile dysfunction (ed) in adult males; moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: colloidal anhydrous silica; macrogol 8000; macrogol 7000000; hypromellose; butylated hydroxytoluene; iron oxide yellow; magnesium stearate - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamsulosin hydrochloride, quantity: 400 microgram - tablet, modified release - excipient ingredients: quinoline yellow; purified talc; polyethylene oxide; cochineal; microcrystalline cellulose; magnesium stearate; hyprolose; butylated hydroxytoluene; macrogol 400; titanium dioxide; iron oxide black; hypromellose; colloidal anhydrous silica - for the relief of lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alfuzosin hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; ethylcellulose; microcrystalline cellulose; iron oxide yellow; silicon dioxide; mannitol; hypromellose; hydrogenated castor oil; povidone - indicated for the treatment of the functional symptoms of benign prostatic hyperplasia.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; croscarmellose sodium; sodium lauryl sulfate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - tadalafil gh (tadalafil 20 mg tablets) are indicated for the treatment of: ? erectile dysfunction (ed) in adult males.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - tadalafil gh (tadalafil 5 mg tablets) are indicated for the treatment of: ? erectile dysfunction (ed) in adult males; and ? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - tadalafil, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; croscarmellose sodium; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow - tadalafil gh (tadalafil 10 mg tablets) are indicated for the treatment of: ? erectile dysfunction (ed) in adult males.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised potato starch; ascorbyl palmitate; magnesium stearate; lactose monohydrate; lactose - ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women. ? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, <> (tibolone tablets) should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, see clinical trials and precautions). <> (tibolone tablets) should only be continued for as long as the benefit outweighs the risks.